Michael Ezekowitz of the Lankenau Institute for Medical Research and Heart Center in Wynnewood, Pa. and an investigator on the RELY trial comments on the study looking at Boehringer Ingelheim’s drug Pradaxa, or dabigatran, in stroke prevention during the ESC congress in Barcelona.
uk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Trackback